VA DOD Updates Asthma Framework - Top-Institutions - MDSpire

VA DOD Updates Asthma Framework

The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.

  • By

  • Kathryn Wighton

  • February 17, 2026

  • 4 min

Share

Top Institutions in Family Medicine

Brief introduction explaining scope and methodology.

  • #1

    National Heart, Lung, and Blood Institute (NHLBI)
    National Heart, Lung, and Blood Institute (NHLBI)

    Bethesda, MD

    Key Differentiators

    • Pulmonology
    • Immunology
    • Clinical Research

  • #2

    Johns Hopkins Asthma and Allergy Center
    Johns Hopkins Asthma and Allergy Center

    Baltimore, MD

    Key Differentiators

    • Pulmonology
    • Allergy and Immunology
    • Clinical Trials

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Pulmonology
    • Allergy and Immunology
    • Primary Care Integration

  • #4

    University of California, San Francisco (UCSF) Asthma Research Center
    University of California, San Francisco (UCSF) Asthma Research Center

    San Francisco, CA

    Key Differentiators

    • Pulmonology
    • Immunology
    • Health Disparities Research

  • #5

    VA National Center for Health Promotion and Disease Prevention
    VA National Center for Health Promotion and Disease Prevention

    Washington, DC

    Key Differentiators

    • Veterans' Health
    • Pulmonology
    • Clinical Guidelines

Original Source(s)

VA DOD Updates Asthma Framework

  • by Kathryn Wighton

  • February 17, 2026

Related Content

Vitamin D May Reflect Myopia Risk

Narrative review linked lower vitamin D levels to greater myopia risk and higher omega-3 intake to lower risk, though outdoor exposure may explain the vitamin D association.

Co-creating care: Involving children, young people, and families in paediatric medical device innovation

Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.